Literature DB >> 2254110

Cisplatin and radiation: interaction probabilities and therapeutic possibilities.

A C Begg1.   

Abstract

This paper examines the probability of interactions occurring between drug lesions and radiation lesions in DNA for the cytotoxic and radiosensitizing agent cisplatin. The number of cisplatin-induced DNA adducts and radiation-induced strand breaks after a given dose of each agent are known for given cell systems, from which the probability that these lesions will interact can be estimated. Results of these calculations indicate that the probability of interaction could be high, depending on the distance over which two lesions can interact and the probability of repair of the interaction lesion. Calculated lesion numbers have been compared with known data on radiation modification, including illustrations of inconsistencies. In the second part of the paper, ways in which combined therapy with cisplatin and radiation can be improved are described. Development of methods to predict which types of tumor and which individual tumors within a given type are sensitive to the cytotoxic and radiosensitizing effects of the drug would aid rational selection of patients for combination treatments. Immunocytochemical methods sensitive enough to monitor cisplatin-DNA interactions in patients are available and may be useful in this context. The delivery and maintenance of higher tumour concentrations of radiosensitizer offers a further possibility for improvement. Studies of intratumoral injection of cisplatin have shown promise for achieving this goal while limiting normal tissue toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254110     DOI: 10.1016/0360-3016(90)90226-a

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Concurrent chemotherapy and radiation therapy in primary cancer of the cervix.

Authors:  J M Schilder; F B Stehman
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

3.  Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery.

Authors:  Pradeep Rajkumar; Binu Susan Mathew; Saikat Das; Rajesh Isaiah; Subashini John; Ratna Prabha; Denise Helen Fleming
Journal:  J Clin Diagn Res       Date:  2016-07-01

4.  Combined effects of cisplatin and photon or proton irradiation in cultured cells: radiosensitization, patterns of cell death and cell cycle distribution.

Authors:  Hiromitsu Iwata; Tsuyoshi Shuto; Shunsuke Kamei; Kohei Omachi; Masataka Moriuchi; Chihiro Omachi; Toshiyuki Toshito; Shingo Hashimoto; Koichiro Nakajima; Chikao Sugie; Hiroyuki Ogino; Hirofumi Kai; Yuta Shibamoto
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

5.  Concomitant radiochemotherapy with 5-FU and cisplatin for invasive bladder cancer. Acute toxicity and first results.

Authors:  S Birkenhake; S Leykamm; P Martus; R Sauer
Journal:  Strahlenther Onkol       Date:  1999-03       Impact factor: 3.621

6.  Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study.

Authors:  George Fountzilas; Elisabeta Ciuleanu; Urania Dafni; George Plataniotis; Anna Kalogera-Fountzila; Epaminontas Samantas; Eleni Athanassiou; John Tzitzikas; Tudor Ciuleanu; Angelos Nikolaou; Panayiotis Pantelakos; Thomas Zaraboukas; Nikolaos Zamboglou; John Daniilidis; Nicolas Ghilezan
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

7.  Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.

Authors:  E E Vokes; D J Haraf; P C Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.

Authors:  E E Vokes; D J Haraf; L C Drinkard; P C Hoffman; M K Ferguson; N J Vogelzang; S Watson; N J Lane; H M Golomb
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts.

Authors:  C P Diggle; J Bentley; M A Knowles; A E Kiltie
Journal:  Nucleic Acids Res       Date:  2005-05-04       Impact factor: 16.971

10.  Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.

Authors:  Satoshi Osawa; Takahisa Furuta; Ken Sugimoto; Takashi Kosugi; Tomohiro Terai; Mihoko Yamade; Yasuhiro Takayanagi; Masafumi Nishino; Yasushi Hamaya; Chise Kodaira; Takanori Yamada; Moriya Iwaizumi; Kosuke Takagaki; Ken-ichi Yoshida; Shigeru Kanaoka; Mutsuhiro Ikuma
Journal:  BMC Cancer       Date:  2009-11-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.